trial

Remediation of Auditory Recognition in Schizophrenia With tDCS

NCTId NCT02869334
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 20 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2020-01-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
20 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-06
Primary completion
2020-01-31
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Active Transcranial direct current stimulation (tDCS)Auditory Remediation

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
Nathan Kline Institute for Psychiatric ResearchCollaborator

Investigators

1
Daniel C. Javitt, MD, PhDPrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
20
Phase
NA
Primary Completion Date
2020-01-31
Status
COMPLETED
relationships
The graph out of here
drug
Active Transcranial direct current stimulation (tDCS)
drug
Auditory Remediation
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
Nathan Kline Institute for Psychiatric Research
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Daniel C. Javitt, MD, PhD
person